Trial Profile
A Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of an Etoricoxib and Tizanidine Fixed Dose Combination in Subjects With Moderate to Severe Acute Low Back Pain
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Etoricoxib/tizanidine (Primary) ; Meloxicam; Methocarbamol; Paracetamol
- Indications Back pain
- Focus Adverse reactions; Registrational
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 26 Apr 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 17 Nov 2013 New trial record